PolyPid (NASDAQ:PYPD) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) Head-To-Head Survey

Crinetics Pharmaceuticals (NASDAQ:CRNX) and PolyPid (NASDAQ:PYPD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Crinetics Pharmaceuticals and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	N/A	-35.09%	-32.04%
PolyPid	N/A	-313.65%	-128.32%

Insider & Institutional Ownership

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Crinetics Pharmaceuticals and PolyPid”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$1.04 million	4,375.89	-$298.41 million	($4.53)	-10.59
PolyPid	N/A	N/A	-$29.02 million	($2.98)	-1.37

PolyPid has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Crinetics Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Crinetics Pharmaceuticals and PolyPid, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1	2	11	0	2.71
PolyPid	1	0	6	1	2.88

Crinetics Pharmaceuticals currently has a consensus price target of $77.55, suggesting a potential upside of 61.69%. PolyPid has a consensus price target of $12.40, suggesting a potential upside of 204.67%. Given PolyPid’s stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Crinetics Pharmaceuticals.

Summary

PolyPid beats Crinetics Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.